Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | glioblastoma |
Response Type | conflicting |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | glioblastoma | conflicting | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive glioblastoma (PMID: 31812554; NCT02332668). | 31812554 |
CD274 positive | glioblastoma | conflicting | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). | 30742119 |
CD274 positive | glioblastoma | conflicting | Pembrolizumab | Phase Ib/II | Actionable | In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM) | Full reference... | |
(30742119) | Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. | Full reference... |
(31812554) | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Full reference... |